on PolyPeptide Group
PolyPeptide Group: Samsung Biologics' Tender Offer Provisional Results
Samsung Biologics Co., Ltd., through its subsidiary Samsung Peptide AG, has announced the provisional results of its public tender offer for PolyPeptide Group AG. As of October 30, 2026, Samsung Peptide holds 97.99% of PolyPeptide's share capital and voting rights.
The tender offer, closing its additional acceptance period on October 30, saw 97.66% of PolyPeptide shares tendered. The results remain subject to regulatory approvals. The transaction's completion is anticipated by late 2026 or Q1 2027.
Samsung Peptide plans to execute a squeeze-out of remaining shareholders and seeks to delist PolyPeptide shares following the offer's settlement.
R. H.
Copyright © 2026 FinanzWire, all reproduction and representation rights reserved.
Disclaimer: although drawn from the best sources, the information and analyzes disseminated by FinanzWire are provided for informational purposes only and in no way constitute an incentive to take a position on the financial markets.
Click here to consult the press release on which this article is based
See all PolyPeptide Group news